# SPECIALTY QUANTITY LIMIT PROGRAM

## **EMFLAZA** (deflazacort)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of Duchenne muscular dystrophy fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-Recommended Dosing
Emflaza tablets 6 mg	60 tablets per 30 days	
Emflaza tablets 18 mg	30 tablets per 30 days	0.9 mg/kg/day*
Emflaza tablets 30 mg	30 tablets per 30 days	
Emflaza tablets 36 mg	30 tablets per 30 days	
Emflaza suspension: 22.75 mg/mL	52 mL per 30 days (1.8 mL/day)	

\* The maximum dose of deflazacort recommended by clinical practice guidelines is 36 to 39 mg per day.

#### **III. REFERENCES**

- 1. Emflaza [package insert]. Northbrook, IL: Marathon Pharmaceuticals, LLC; June 2017.
- 2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis and pharmacological and psychosocial management. *Lancet Neurol*. 2010;9:77-93.

Specialty Quantity Limit Emflaza 1637-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

